Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1424170rdf:typepubmed:Citationlld:pubmed
pubmed-article:1424170lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:1424170lifeskim:mentionsumls-concept:C1533685lld:lifeskim
pubmed-article:1424170lifeskim:mentionsumls-concept:C0006230lld:lifeskim
pubmed-article:1424170lifeskim:mentionsumls-concept:C1272936lld:lifeskim
pubmed-article:1424170lifeskim:mentionsumls-concept:C0376315lld:lifeskim
pubmed-article:1424170lifeskim:mentionsumls-concept:C0086466lld:lifeskim
pubmed-article:1424170lifeskim:mentionsumls-concept:C1272883lld:lifeskim
pubmed-article:1424170pubmed:issue4lld:pubmed
pubmed-article:1424170pubmed:dateCreated1992-12-2lld:pubmed
pubmed-article:1424170pubmed:abstractTextThe objective of this study was to assess the relationship of different doses of a long-acting bromocriptine preparation (Parlodel LAR) to the degree and duration of PRL suppression. We also measured circulating bromocriptine levels and altered tolerability of the drug.lld:pubmed
pubmed-article:1424170pubmed:languageenglld:pubmed
pubmed-article:1424170pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1424170pubmed:citationSubsetIMlld:pubmed
pubmed-article:1424170pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1424170pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1424170pubmed:statusMEDLINElld:pubmed
pubmed-article:1424170pubmed:monthAprlld:pubmed
pubmed-article:1424170pubmed:issn0300-0664lld:pubmed
pubmed-article:1424170pubmed:authorpubmed-author:LancranjanIIlld:pubmed
pubmed-article:1424170pubmed:authorpubmed-author:PaganiGGlld:pubmed
pubmed-article:1424170pubmed:authorpubmed-author:MontiniMMlld:pubmed
pubmed-article:1424170pubmed:authorpubmed-author:GianolaDDlld:pubmed
pubmed-article:1424170pubmed:authorpubmed-author:GherardiFFlld:pubmed
pubmed-article:1424170pubmed:authorpubmed-author:PaganiM DMDlld:pubmed
pubmed-article:1424170pubmed:authorpubmed-author:PedroncelliAAlld:pubmed
pubmed-article:1424170pubmed:authorpubmed-author:TengattiniFFlld:pubmed
pubmed-article:1424170pubmed:authorpubmed-author:CortesiLLlld:pubmed
pubmed-article:1424170pubmed:authorpubmed-author:MazzocchiNNlld:pubmed
pubmed-article:1424170pubmed:issnTypePrintlld:pubmed
pubmed-article:1424170pubmed:volume36lld:pubmed
pubmed-article:1424170pubmed:ownerNLMlld:pubmed
pubmed-article:1424170pubmed:authorsCompleteYlld:pubmed
pubmed-article:1424170pubmed:pagination369-74lld:pubmed
pubmed-article:1424170pubmed:dateRevised2010-3-24lld:pubmed
pubmed-article:1424170pubmed:meshHeadingpubmed-meshheading:1424170-...lld:pubmed
pubmed-article:1424170pubmed:meshHeadingpubmed-meshheading:1424170-...lld:pubmed
pubmed-article:1424170pubmed:meshHeadingpubmed-meshheading:1424170-...lld:pubmed
pubmed-article:1424170pubmed:meshHeadingpubmed-meshheading:1424170-...lld:pubmed
pubmed-article:1424170pubmed:meshHeadingpubmed-meshheading:1424170-...lld:pubmed
pubmed-article:1424170pubmed:meshHeadingpubmed-meshheading:1424170-...lld:pubmed
pubmed-article:1424170pubmed:meshHeadingpubmed-meshheading:1424170-...lld:pubmed
pubmed-article:1424170pubmed:meshHeadingpubmed-meshheading:1424170-...lld:pubmed
pubmed-article:1424170pubmed:year1992lld:pubmed
pubmed-article:1424170pubmed:articleTitleEfficacy of a new long-acting injectable form of bromocriptine in hyperprolactinaemic patients.lld:pubmed
pubmed-article:1424170pubmed:affiliationDivision of Endocrinology, Ospedali Riuniti, Bergamo, Italy.lld:pubmed
pubmed-article:1424170pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1424170pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:1424170pubmed:publicationTypeRandomized Controlled Triallld:pubmed